NKGN (NKGen Biotech) Interest Coverage : 0 (At Loss) (As of Sep. 2024)

View and export this data going back to 2023. Start your Free Trial

What is NKGen Biotech Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. NKGen Biotech's Operating Income for the three months ended in Sep. 2024 was $-6.79 Mil. NKGen Biotech's Interest Expense for the three months ended in Sep. 2024 was $-0.47 Mil. did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is.

The historical rank and industry rank for NKGen Biotech's Interest Coverage or its related term are showing as below:

NKGN's Interest Coverage is not ranked ^*
in the Biotechnology industry.
Industry Median: 101.38
* Ranked among companies with meaningful Interest Coverage only.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

NKGen Biotech Interest Coverage Historical Data

The historical data trend for NKGen Biotech's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

NKGen Biotech Interest Coverage Chart

NKGen Biotech Annual Data

Trend

Dec21

Dec22

Dec23

Interest Coverage

NKGen Biotech Quarterly Data
	Dec21	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Interest Coverage	Get a 7-Day Free Trial					-	-	-	-	-

Competitive Comparison of NKGen Biotech's Interest Coverage

For the Biotechnology subindustry, NKGen Biotech's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NKGen Biotech's Interest Coverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NKGen Biotech's Interest Coverage distribution charts can be found below:

* The bar in red indicates where NKGen Biotech's Interest Coverage falls into.

Save Embed

;

Save Embed

;

NKGen Biotech Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage

-1

Operating Income

Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt ⁽¹⁾.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

NKGen Biotech's Interest Coverage for the fiscal year that ended in Dec. 2023 is calculated as

Here, for the fiscal year that ended in Dec. 2023, NKGen Biotech's Interest Expense was $-0.75 Mil. Its Operating Income was $-29.75 Mil. And its Long-Term Debt & Capital Lease Obligation was $9.93 Mil.

NKGen Biotech did not have earnings to cover the interest expense.

NKGen Biotech's Interest Coverage for the quarter that ended in Sep. 2024 is calculated as

Here, for the three months ended in Sep. 2024, NKGen Biotech's Interest Expense was $-0.47 Mil. Its Operating Income was $-6.79 Mil. And its Long-Term Debt & Capital Lease Obligation was $10.89 Mil.

NKGen Biotech did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's Financial Strength is.

NKGen Biotech (OTCPK:NKGN) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .

NKGen Biotech Interest Coverage Related Terms

Thank you for viewing the detailed overview of NKGen Biotech's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.

NKGen Biotech Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NKGen Biotech Inc (OTCPK:NKGN) » Definitions » Interest Coverage

Comparable Companies

Traded in Other Exchanges

N/A

Address

3001 Daimler Street, Santa Ana, CA, USA, 92705

Website

https://www.nkgenbiotech.com

NKGen Biotech Inc is a biotechnology company developing cell therapies for neurodegenerative and oncological diseases based on activated NK cells. NK cells are part of the human innate immune response system that can selectively identify and destroy abnormal or diseased cells. Its product candidates are based on a proprietary manufacturing and cryopreservation process that produces SuperNKTM (SNK) cells that have shown increased activity as compared to the starting population of NK cells, based on the results of in vitro experiments performed by NKMAX, as defined by parameters such as cytotoxicity, cytokine production and activating receptor expression. SNK cells can be produced in large quantities and cryopreserved while maintaining high levels of cytotoxicity.